Enanta Pharmaceuticals Management
Management criteria checks 3/4
Enanta Pharmaceuticals' CEO is Jay Luly, appointed in Jul 2003, has a tenure of 21.67 years. total yearly compensation is $2.70M, comprised of 28.9% salary and 71.1% bonuses, including company stock and options. directly owns 3.88% of the company’s shares, worth $5.21M. The average tenure of the management team and the board of directors is 4.2 years and 8.3 years respectively.
Key information
Jay Luly
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 28.9% |
| CEO tenure | 21.7yrs |
| CEO ownership | 3.9% |
| Management average tenure | 4.2yrs |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry
Feb 14
Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report
Nov 30Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet
Nov 27Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?
Oct 05Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results
Aug 08Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%
Jul 24Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Jun 19Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Mar 05Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Aug 13We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed
Feb 24Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade
Feb 08Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta starts mid-stage trial of EDP-938 for RSV infection
Oct 03Enanta Pharma FQ3 2022 Earnings Preview
Aug 07Enanta potential COVID drug shows safety in healthy people in early-stage trial
Jul 29Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Enanta: Slow Drip
May 17Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Feb 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | -US$105m |
| Sep 30 2024 | US$3m | US$780k | -US$116m |
| Jun 30 2024 | n/a | n/a | -US$115m |
| Mar 31 2024 | n/a | n/a | -US$132m |
| Dec 31 2023 | n/a | n/a | -US$138m |
| Sep 30 2023 | US$8m | US$755k | -US$134m |
| Jun 30 2023 | n/a | n/a | -US$132m |
| Mar 31 2023 | n/a | n/a | -US$125m |
| Dec 31 2022 | n/a | n/a | -US$121m |
| Sep 30 2022 | US$7m | US$725k | -US$122m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$101m |
| Sep 30 2021 | US$5m | US$693k | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$74m |
| Dec 31 2020 | n/a | n/a | -US$58m |
| Sep 30 2020 | US$5m | US$667k | -US$36m |
| Jun 30 2020 | n/a | n/a | US$2m |
| Mar 31 2020 | n/a | n/a | US$24m |
| Dec 31 2019 | n/a | n/a | US$34m |
| Sep 30 2019 | US$4m | US$642k | US$46m |
| Jun 30 2019 | n/a | n/a | US$65m |
| Mar 31 2019 | n/a | n/a | US$78m |
| Dec 31 2018 | n/a | n/a | US$86m |
| Sep 30 2018 | US$4m | US$611k | US$72m |
Compensation vs Market: Jay's total compensation ($USD2.70M) is above average for companies of similar size in the US market ($USD638.32K).
Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.
CEO
Jay Luly (68 yo)
21.7yrs
Tenure
US$2,695,276
Compensation
Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer, President and Director of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxfor...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 21.7yrs | US$2.70m | 3.88% $ 5.2m | |
| Chief Financial & Administrative Officer | 21.5yrs | US$1.14m | 0.39% $ 527.2k | |
| Chief Scientific Officer | 25.3yrs | US$1.22m | 1.7% $ 2.3m | |
| Chief Legal Officer & Corporate Secretary | less than a year | US$1.74m | no data | |
| Chief Medical Office | 2.6yrs | US$1.26m | 0.053% $ 71.2k | |
| Executive Director of Investor Relations & Corporate Communications | no data | no data | no data | |
| Consultant | 1yr | US$2.86m | 0.42% $ 570.5k | |
| Chief Product Strategy Officer | 4.3yrs | US$2.10m | 0.11% $ 141.9k | |
| Chief Business Officer | 4.2yrs | US$2.58m | 0.14% $ 184.4k |
4.2yrs
Average Tenure
59.5yo
Average Age
Experienced Management: ENTA's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 21.7yrs | US$2.70m | 3.88% $ 5.2m | |
| Independent Director | 4.8yrs | US$331.41k | 0% $ 0 | |
| Independent Non-Executive Chairman | 11.3yrs | US$353.91k | 0% $ 0 | |
| Independent Director | 13.8yrs | US$333.91k | 0.027% $ 36.5k | |
| Independent Director | 7.5yrs | US$326.41k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$318.91k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$321.41k | 0% $ 0 |
8.3yrs
Average Tenure
65yo
Average Age
Experienced Board: ENTA's board of directors are considered experienced (8.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/19 11:52 |
| End of Day Share Price | 2025/03/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enanta Pharmaceuticals, Inc. is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |